When you start assuming withdrawals, even bad income picks outperform a portfolio forced to sell at low prices. Learn more ...

Innovex is transitioning from a cyclical equipment supplier to a capital-light consolidator leveraging global distribution ...

The Global Adaptive Capital Appreciation Managed Account returned 10.15% in Q2 2026, beating its benchmark. Read the full ...

Nvidia's growth engine is far from peaking, translating into a solid outlook of 70% FY2028 revenue growth and robust AI chip ...

INNIO offers a compelling pick-and-shovel play on the data center boom, with strong sales momentum and a robust order backlog ...

In the second quarter, the Lazard Real Assets Portfolio's institutional shares appreciated 1.2%, outperforming the 0.4% gain ...

Carlsberg is transitioning from a traditional brewer to a diversified beverage platform. Find out why CABGY stock is a Hold.

Vitalhub is growing ARR while integrating acquisitions and expanding margins. Click here to see why VHI:CA stock is a Buy.

Shein’s Hong Kong IPO at a $26B valuation faces investor concerns over growth outlook, tariffs, and rising competition.

Revolution Medicines (RVMD) gets FDA approval for RASONQUE and advances zoldonrasib Phase 3 trials—see upside, cash runway ...

Copart remains a global leader in vehicle remarketing, but current valuation and macro headwinds justify a 'hold' rating. US ...

The TCW MetWest Low Duration Bond Fund outperformed its index in Q2 2026 amid Middle East volatility. Read the full analysis ...